Skip to main content

Response Genetics Prices $4.8M Stock Offering

NEW YORK (GenomeWeb News) – Response Genetics has launched a public offering of nearly 4.5 million shares of its common stock at $1.20 per share.

The Los Angeles-based molecular diagnostics firm said that it expects to raise about $4.8 million in net proceeds, which it will use for working capital and general corporate purposes. It could realize additional proceeds if underwriters of the offering exercise their over-allotment option of 669,666 shares.

The offering price is below Thursday's closing price on the Nasdaq of $1.32, and shares of Response Genetics dropped nearly 11 percent to $1.18 in early Friday trade after the offering was priced.

Last month the firm announced a 24 percent decline in Q3 revenues year over year and ended the quarter with $4.6 million in cash and cash equivalents. It subsequently announced that it had signed on four payors to provide access to the molecular diagnostic firm's tests.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.